Impel Pharmaceuticals Inc IMPL
We take great care to ensure that the data presented and summarized in this overview for IMPEL PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMPL
View allLatest Institutional Activity in IMPL
Top Purchases
Top Sells
About IMPL
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Insider Transactions at IMPL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 05
2024
|
Timothy S Nelson |
SELL
Other acquisition or disposition
|
Direct |
10,000
-100.0%
|
-
|
|
Dec 19
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
237,289
-9.3%
|
$0
$0.08 P/Share
|
|
Dec 18
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
237,711
-8.52%
|
$0
$0.11 P/Share
|
|
Dec 15
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-3.46%
|
$0
$0.29 P/Share
|
|
Dec 31
2022
|
John Harold Leaman Chief Fin. & Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,627
-34.31%
|
$10,881
$3.75 P/Share
|
|
Dec 31
2022
|
John Harold Leaman Chief Fin. & Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,571
+50.0%
|
-
|
|
Mar 29
2022
|
Stephen B Shrewsbury Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,606
+20.07%
|
$24,606
$1.97 P/Share
|
|
Dec 22
2021
|
John Hoekman Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+13.49%
|
$20,000
$1.64 P/Share
|
|
Nov 19
2021
|
Timothy S Nelson |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$100,000
$10.76 P/Share
|
|
Sep 21
2021
|
Stephen B Shrewsbury Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
73,384
+37.23%
|
$146,768
$2.46 P/Share
|
|
Aug 18
2021
|
Adrian Adams COB, CEO and President |
BUY
Open market or private purchase
|
Direct |
20,000
+21.03%
|
$280,000
$14.87 P/Share
|
|
Apr 27
2021
|
John Hoekman Chief Scientific Officer |
SELL
Other acquisition or disposition
|
Direct |
275
-0.25%
|
-
|
|
Apr 27
2021
|
John Hoekman Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
4,523
+4.0%
|
-
|
|
Apr 27
2021
|
H Stewart Parker Director |
BUY
Conversion of derivative security
|
Direct |
20,151
+30.63%
|
$261,963
$13.5 P/Share
|
|
Apr 27
2021
|
H Stewart Parker Director |
SELL
Other acquisition or disposition
|
Direct |
2,124
-6.35%
|
-
|
|
Apr 27
2021
|
Ven Bio Global Strategic Fund Ii L.P. |
BUY
Open market or private purchase
|
Direct |
450,000
+14.02%
|
$6,750,000
$15.0 P/Share
|
|
Apr 27
2021
|
Ven Bio Global Strategic Fund Ii L.P. |
BUY
Conversion of derivative security
|
Direct |
2,309,791
+50.0%
|
-
|
|
Apr 27
2021
|
Norwest Venture Partners Xiv, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
825,000
+21.14%
|
$12,375,000
$15.0 P/Share
|
|
Apr 27
2021
|
Norwest Venture Partners Xiv, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,252,198
+49.44%
|
$13,513,188
$6.75 P/Share
|
|
Apr 27
2021
|
5 Am Ventures V, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
575,000
+50.0%
|
$8,625,000
$15.0 P/Share
|
Last 12 Months Summary
| Open market or private sale | 575K shares |
|---|---|
| Other acquisition or disposition | 10K shares |